Active Ingredient(s): Neostigmine Methylsulfate
FDA Approved: * May 31, 2013
Pharm Company: * ECLAT PHARMS LLC
Category: Myasthenic Syndrome

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Bloxiverz Overview

Neostigmine is a medication used to treat myasthenia gravis, Ogilvie syndrome, and urinary retention without the presence of a blockage.[2][3] It is also used together with atropine to end the effects of neuromuscular blocking medication of the non-depolarizing type.[2] It is given by injection either into a vein, muscle, or under the skin.[2] After injection effects are generally greatest within 30 minutes and last up to 4 hours...

Read more Bloxiverz Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Bloxiverz Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Neostigmine Methylsulfate
  • Injection: 0.25mg/ml, 0.5mg/ml, 1mg/ml
  • Solution: 10mg/10ml (1mg/ml), 5mg/10ml (0.5mg/ml)
  • Tablet: 15mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Bloxiverz: (5 results)

Sorted by National Drug Code
  • 68001-329 Bloxiverz 1 mg/ml Intravenous Injection by Bluepoint Laboratories
  • 76014-002 Bloxiverz .5 mg/ml Intravenous Injection by Eclat Pharmaceuticals, LLC
  • 76014-003 Bloxiverz 1 mg/ml Intravenous Injection by Eclat Pharmaceuticals, LLC
  • 76014-902 Bloxiverz .5 mg/ml Intravenous Injection by Eclat Pharmaceuticals, LLC
  • 76014-903 Bloxiverz 1 mg/ml Intravenous Injection by Eclat Pharmaceuticals, LLC

Other drugs which contain Neostigmine Methylsulfate or a similar ingredient: (2 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 1 March 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA